PMID: 18434965Apr 25, 2008Paper

AML1 and Evi1: coconspirators in MDS/AML?

Blood
Timothy Graubert

Abstract

In this issue of Blood, Watanabe-Okochi and colleagues use a mouse bone marrow transplantation model to demonstrate that mutant alleles of AML1 (RUNX1) can initiate a myelodysplastic syndrome (MDS) that progresses to acute myelogenous leukemia (AML) in association with overexpression of Evi1.

References

May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·K MorishitaJ N Ihle
Sep 3, 2004·The Journal of Clinical Investigation·Silvia BuonamiciGiuseppina Nucifora
Jun 19, 2007·Cancer Research·Vitalyi SenyukGiuseppina Nucifora

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.